Clinical Trial Update: Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Inotuzumab Ozogamicin for relapsed or refractory CD22-positive acute lymphoblastic leukemia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: CD22 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2021-04-12